How should I manage a patient with acute upper gastrointestinal bleeding from a bleeding peptic ulcer, including resuscitation, blood transfusion, reversal of anticoagulants, high‑dose intravenous proton‑pump inhibitor therapy, urgent endoscopy with endoscopic hemostasis, H. pylori eradication, NSAID cessation, and second‑line interventions if needed?

Management of Acute Upper Gastrointestinal Bleeding from Peptic Ulcer Disease

Begin immediate resuscitation with 1–2 liters of isotonic crystalloid through two large-bore peripheral IVs, transfuse red blood cells when hemoglobin falls below 80 g/L (higher threshold for cardiovascular disease), start pantoprazole 80 mg IV bolus followed by 8 mg/hour continuous infusion, and perform endoscopy within 24 hours (within 12 hours if hemodynamically unstable) with combination endoscopic therapy for high-risk stigmata. 1, 2

Immediate Resuscitation and Stabilization

Fluid Resuscitation

• Establish two large-bore peripheral IV lines and infuse 1–2 liters of isotonic crystalloid (normal saline or Ringer's lactate) targeting systolic blood pressure >90 mmHg, heart rate <100 bpm, central venous pressure 5–10 cm H₂O, and urine output >30 mL/hour 1, 2
• Crystalloids are preferred over colloids because colloids show no survival benefit and are more expensive 1, 2
• If shock persists after 2 liters, plasma expanders are needed as ≥20% of blood volume has been lost 2

Blood Transfusion Strategy

• Transfuse packed red blood cells when hemoglobin is <80 g/L (8 g/dL) in patients without cardiovascular disease 1, 2
• Use a higher hemoglobin threshold (generally >80–90 g/L) for patients with ischemic heart disease, heart failure, or age >60 years 1, 2

Airway Protection

• Intubate patients with massive hematemesis, altered mental status, or severe hypoxemia (oxygen saturation ≈85%) before endoscopy to prevent aspiration 2

Monitoring

• Insert a urinary catheter and monitor hourly urine output targeting >30 mL/hour in patients with severe bleeding 1, 2
• Apply continuous automated blood pressure and heart rate monitoring for hemodynamically unstable patients 2

Risk Stratification

High-Risk Features Requiring ICU Admission

• Age >60 years (mortality 30% in patients >90 years versus rare in patients <40 years) 2
• Shock defined as heart rate >100 bpm and systolic blood pressure <100 mmHg 1, 2
• Hemoglobin <100 g/L at presentation 2
• Major comorbidities: renal failure, liver failure, ischemic heart disease, heart failure, or disseminated malignancy 2

Low-Risk Identification

• Use Glasgow Blatchford score ≤1 to identify very low-risk patients who may be managed as outpatients without hospitalization or urgent endoscopy 1, 2
• Do not use the AIMS65 score for risk stratification as it is not recommended 1

Pre-Endoscopic Pharmacologic Management

Proton Pump Inhibitor Therapy

• Start pantoprazole 80 mg IV bolus followed by 8 mg/hour continuous infusion immediately upon presentation, before endoscopy 1, 2, 3
• This regimen may downstage endoscopic lesions and decrease the need for intervention but should not delay endoscopy 1, 2

Agents to Avoid

• Do not use promotility agents (erythromycin or metoclopramide) routinely before endoscopy as they do not improve outcomes 1, 2
• Do not use H₂-receptor antagonists as they are ineffective for acute ulcer bleeding 3, 4

Anticoagulation Management

• Do not delay endoscopy in patients receiving warfarin or direct oral anticoagulants (DOACs); proceed with endoscopy and hemostatic therapy as needed 1, 2

Nasogastric Tube

• Nasogastric tube placement is not routinely required; consider only in selected patients for prognostic information (bright blood indicates higher rebleeding risk) 1, 2

Special Consideration for Cirrhosis

• If cirrhosis or chronic liver disease is suspected, presume variceal bleeding until proven otherwise and start vasoactive therapy (octreotide 50 µg IV bolus then 50 µg/hour infusion or somatostatin 250 µg IV bolus then 250 µg/hour infusion) plus antibiotic prophylaxis (ceftriaxone 1 g IV daily) immediately 2

Timing of Endoscopy

• Perform endoscopy within 24 hours of presentation for all hospitalized patients after initial hemodynamic stabilization 1, 2, 3
• For high-risk patients with persistent hemodynamic instability (shock index ≥1), altered mental status, or suspected variceal bleeding, perform urgent endoscopy within 12 hours 1, 2, 3

Endoscopic Hemostatic Therapy

High-Risk Stigmata (Forrest Ia, Ib, IIa)

• For active bleeding (Forrest Ia, Ib) or visible vessel (Forrest IIa), apply combination therapy: epinephrine injection plus a second modality (thermal coagulation, sclerosant injection, or through-the-scope clips) 1, 2, 3, 5
• Epinephrine injection alone is insufficient and must never be used as sole therapy because it provides suboptimal efficacy 1, 2, 3, 5
• Thermal coagulation options include bipolar electrocoagulation or heater probe 1, 2
• Combination therapy reduces rebleeding (OR 0.19,95% CI 0.07–0.52) and need for surgery (OR 0.10,95% CI 0.01–0.50) 5

Adherent Clot (Forrest IIb)

• Perform vigorous targeted irrigation for at least 5 minutes using water pump irrigation to attempt clot dislodgement 1, 2, 5
• If underlying high-risk stigmata are exposed (occurs in 26–43% of cases), treat with combination therapy as above 5
• Avoid aggressive mechanical dislodgment as it increases perforation risk; use cautious irrigation-based approaches 5

Low-Risk Stigmata (Forrest IIc, III)

• Endoscopic hemostatic therapy is not indicated for clean-based ulcers (Forrest III) or flat pigmented spots (Forrest IIc) 1, 2, 3

Post-Endoscopic Management

High-Dose PPI Therapy

• After successful endoscopic hemostasis of high-risk lesions, continue pantoprazole 8 mg/hour IV infusion for a total of 72 hours (including the initial bolus) 1, 2, 3, 5
• This regimen reduces rebleeding from 10.3% to 5.9% (p=0.03) 5, 6, 7
• After 72 hours, switch to oral PPI (pantoprazole 40 mg) twice daily for 14 days, then once daily thereafter 1, 2, 3

Monitoring and Admission

• Admit patients who received endoscopic therapy for high-risk lesions to a monitored setting (ICU or step-down unit) for at least 72 hours because the peak rebleeding risk occurs within this window 1, 2, 3
• Low-risk patients (Forrest IIc, III) may resume oral intake within 24 hours and be discharged promptly if hemodynamically stable 1, 2, 3

Dietary Advancement

• High-risk patients (Forrest Ia–IIb) should remain NPO during the 72-hour IV PPI infusion; advance diet only after this period if no rebleeding occurs 3
• Low-risk patients (Forrest IIc, III) may be fed immediately after endoscopy with no dietary restrictions 3

Management of Rebleeding

• If rebleeding occurs (hematemesis, melena, hemodynamic deterioration, falling hemoglobin), perform repeat endoscopy with hemostasis as the first-line approach 1, 2, 3, 5
• If repeat endoscopy fails, obtain CT angiography to localize the bleeding source (sensitivity 79–95%, specificity 95–100%) 2
• When endoscopic therapy fails twice, consider transcatheter angiographic embolization (success rate 88–100%) or surgical intervention 2, 3

Helicobacter pylori Management

• Test all patients with bleeding peptic ulcers for H. pylori using biopsy during endoscopy and initiate eradication therapy if positive 1, 2, 3, 8, 9
• Eradication reduces ulcer recurrence and rebleeding rates by >80% 3, 8, 9
• Because acute bleeding yields false-negative results in 25–55% of cases, perform confirmatory testing (urea breath test or stool antigen) 4–6 weeks after the acute episode if the initial test is negative 2, 3
• Confirm successful eradication with a urea breath test or stool antigen 4–6 weeks after completing therapy 3

NSAID Cessation and Secondary Prevention

NSAID Management

• Discontinue NSAIDs immediately in all patients with bleeding peptic ulcers 2, 9
• If NSAIDs are essential long-term, prescribe a COX-2-selective inhibitor plus a PPI (COX-2 inhibitor alone is insufficient) 3, 9

Antiplatelet Therapy Resumption

• Restart aspirin for cardiovascular prophylaxis when cardiovascular benefit outweighs bleeding risk—typically 1–7 days after confirmed hemostasis (thrombotic risk rises rapidly after 7 days) 1, 2, 3, 9
• Aspirin plus PPI is superior to clopidogrel alone for preventing rebleeding 1, 2, 3
• All patients with prior ulcer bleeding who require antiplatelet or anticoagulant therapy should receive indefinite PPI co-therapy 1, 2, 3, 9

Critical Pitfalls to Avoid

• Do not perform endoscopy before adequate hemodynamic stabilization and airway protection in unstable patients 2, 3
• Do not use epinephrine injection alone for endoscopic hemostasis; it must be combined with thermal or mechanical therapy 1, 2, 3, 5
• Do not replace aspirin with clopidogrel monotherapy in patients with prior GI bleeding; aspirin plus PPI provides better protection 1, 2, 3
• Do not delay aspirin resumption beyond 7 days in patients needing cardiovascular prophylaxis 3
• Do not discontinue PPI therapy once the acute bleed resolves; lifelong PPI is recommended for patients on antiplatelet agents with a history of bleeding 3
• Do not aggressively mechanically dislodge adherent clots; use cautious irrigation for at least 5 minutes 5
• Do not discharge high-risk patients before completing the 72-hour observation period because late rebleeding carries significant mortality 3